ARTICLE | Company News
Orgenesis, Tel Hashomer Medical Research Infrastructure and Services Ltd. deal
April 16, 2012 7:00 AM UTC
Tel Hashomer will begin a trial to evaluate functional autologous insulin-producing cells (AIPC) regeneration technology as a therapy for diabetes under the supervision of Orgenesis. The trial will be...